India's modified Biomedical Research Bill to be sent to Health Ministry soon

6 January 2010

The Indian Council of Medical Research (ICMR) will soon send a modified Biomedical Research Human Subjects Promotion and Regulation Bill to the Union Health Ministry for its final approval before introducing it in Parliament.

The ICMR is currently putting the final touches to the Bill, which mainly incorporates ethical guidelines for biomedical research on human subjects, has been lying dormant since it was cleared by the law ministry way back in January 2006.

Addressing the media at the conclusion of a recent two-day international symposium on stem cell research, Vasantha Muthuswamy, senior deputy director general at the ICMR, said that 'separate legislation will be made to incorporate all aspects and issues pertaining to biomedical research.'

The review committee formed to give final shape to the legislation 'will meet soon and will finalize the Bill,' said ICMR director general Vishwa Mohan Katoch, adding that, since the Bill has been pending for many years, several of its features have become irrelevant and have to be reviewed and changes have to be made accordingly.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology